mgtktjs

Property	Value
?:abstract	INTRODUCTION: Tocilizumab (TCZ) is an interleukin-6 receptor antagonist, which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), which aims to ameliorate the cytokine release syndrome (CRS) induced acute respiratory distress syndrome (ARDS). However, there are no consistent data about who might benefit most from it. METHODS: We administered TCZ on a compassionate-use basis to patients with SSP who were hospitalized (excluding intensive care and intubated cases) and who required oxygen support to have a saturation >93%. The primary endpoint was intubation or death after 24 h of its administration. Patients received at least one dose of 400 mg intravenous TCZ from March 8, 2020 to April 20, 2020. RESULTS: A total of 207 patients were studied and 186 analyzed. The mean age was 65 years and 68% were male patients. A coexisting condition was present in 68% of cases. Prognostic factors of death were older age, higher IL-6, d-dimer and high-sensitivity C-reactive protein (HSCRP), lower total lymphocytes, and severe disease that requires additional oxygen support. The primary endpoint (intubation or death) was significantly worst (37% vs 13%, p < 0·001) in those receiving the drug when the oxygen support was high (FiO2 >0.5%). CONCLUSIONS: TCZ is well tolerated in patients with SSP, but it has a limited effect on the evolution of cases with high oxygen support needs. Introduction: Tocilizumab (TCZ) is an interleukin-6 receptor antagonist, which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), which aims to ameliorate the cytokine release syndrome (CRS) induced acute respiratory distress syndrome (ARDS) However, there are no consistent data about who might benefit most from it Methods: We administered TCZ on a compassionate-use basis to patients with SSP who were hospitalized (excluding intensive care and intubated cases) and who required oxygen support to have a saturation 0 001) in those receiving the drug when the oxygen support was high (FiO2 0 5%) Conclusions: TCZ is well tolerated in patients with SSP, but it has a limited effect on the evolution of cases with high oxygen support needs (C) 2020 The Authors Published by Elsevier Ltd on behalf of International Society for Infectious Diseases
is ?:annotates of	<https://research.tib.eu/covid-19/entity/4mgtktjs_hasAnnotation_C0013227> <https://research.tib.eu/covid-19/entity/4mgtktjs_hasAnnotation_C1874451> <https://research.tib.eu/covid-19/entity/4mgtktjs_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/G%C3%B3rgolas_Hern%C3%A1ndez-Mora%2C_Miguel%3B_Cabello_%C3%9Abeda%2C_Alfonso%3B_Prieto-P%C3%A9rez%2C_Laura%3B_Villar_%C3%81lvarez%2C_Felipe%3B_%C3%81lvarez_%C3%81lvarez%2C_Beatriz%3B_Rodr%C3%ADguez_Nieto%2C_Mar%C3%ADa_Jes%C3%BAs%3B_Carrillo_Acosta%2C_Irene%3B_Fern%C3%A1ndez_Ormaechea%2C_Itziar%3B_Al-Hayani%2C_Aws_Waleed_Mohammed%3B_Carballosa%2C_Pilar%3B_Calpena_Mart%C3%ADnez%2C_Silvia%3B_Ezzine%2C_Farah%3B_Castellanos_Gonz%C3%A1lez%2C_Marina%3B_Naya%2C_Alba%3B_L%C3%B3pez_De_Las_Heras%2C_Marta%3B_Rodr%C3%ADguez_Guzm%C3%A1n%2C_Marcel_Jos%C3%A9%3B_Cordero_Guijarro%2C_Ana%3B_Broncano_Lavado%2C_Antonio%3B_Mac%C3%ADas_Valcayo%2C_Alicia%3B_Mart%C3%ADn_Garc%C3%ADa%2C_Marta%3B_B%C3%A9cares_Mart%C3%ADnez%2C_Javier%3B_Fern%C3%A1ndez_Roblas%2C_Ricardo%3B_Piris_Pinilla%2C_Miguel_%C3%81ngel%3B_Fortes_Alen%2C_Jos%C3%A9%3B_S%C3%A1nchez_Pernaute%2C_Olga%3B_Romero_Bueno%2C_Fredeswinda%3B_Heili-Frades%2C_Sarah%3B_Peces-Barba_Romero%2C_Germ%C3%A1n> <https://research.tib.eu/covid-19/entity/Hernandez-Mora%2C_M._G.%3B_Ubeda%2C_A._C.%3B_Prieto-Perez%2C_L.%3B_Alvarez%2C_F._V.%3B_Alvarez%2C_B._A.%3B_Nieto%2C_M._J._R.%3B_Acosta%2C_I._C.%3B_Ormaechea%2C_I._F.%3B_Al-Hayani%2C_A._W._M.%3B_Carballosa%2C_P.%3B_Martinez%2C_S._C.%3B_Ezzine%2C_F.%3B_Gonzalez%2C_M._C.%3B_Naya%2C_A.%3B_Heras%2C_M._L.%3B_Guzman%2C_M._J._R.%3B_Guijarro%2C_A._C.%3B_Lavado%2C_A._B.%3B_Valcayo%2C_A._M.%3B_Garcia%2C_M._M.%3B_Martinez%2C_J._B.%3B_Roblas%2C_R._F.%3B_Pinilla%2C_M._A._P.%3B_Alen%2C_J._F.%3B_Pernaute%2C_O._S.%3B_Bueno%2C_F._R.%3B_Heili-Frades%2C_S.%3B_Romero%2C_G._P._B.>
?:journal	Int_J_Infect_Dis International_Journal_of_Infectious_Diseases
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/4mgtktjs_HAS_C0948245_CAUSES_C0035222> <https://research.tib.eu/covid-19/entity/4mgtktjs_HAS_C1609165_ASSOCIATED_WITH_C0032285> <https://research.tib.eu/covid-19/entity/4mgtktjs_HAS_C1609165_TREATS_C0948245> <https://research.tib.eu/covid-19/entity/4mgtktjs_HAS_C3653320_TREATS_C0032285>
?:source	WHO
?:title	Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#1060009 #893930
?:year	2021

Property

Value

?:abstract

INTRODUCTION: Tocilizumab (TCZ) is an interleukin-6 receptor antagonist, which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), which aims to ameliorate the cytokine release syndrome (CRS) induced acute respiratory distress syndrome (ARDS). However, there are no consistent data about who might benefit most from it. METHODS: We administered TCZ on a compassionate-use basis to patients with SSP who were hospitalized (excluding intensive care and intubated cases) and who required oxygen support to have a saturation >93%. The primary endpoint was intubation or death after 24 h of its administration. Patients received at least one dose of 400 mg intravenous TCZ from March 8, 2020 to April 20, 2020. RESULTS: A total of 207 patients were studied and 186 analyzed. The mean age was 65 years and 68% were male patients. A coexisting condition was present in 68% of cases. Prognostic factors of death were older age, higher IL-6, d-dimer and high-sensitivity C-reactive protein (HSCRP), lower total lymphocytes, and severe disease that requires additional oxygen support. The primary endpoint (intubation or death) was significantly worst (37% vs 13%, p < 0·001) in those receiving the drug when the oxygen support was high (FiO2 >0.5%). CONCLUSIONS: TCZ is well tolerated in patients with SSP, but it has a limited effect on the evolution of cases with high oxygen support needs.
Introduction: Tocilizumab (TCZ) is an interleukin-6 receptor antagonist, which has been used for the treatment of severe SARS-CoV-2 pneumonia (SSP), which aims to ameliorate the cytokine release syndrome (CRS) induced acute respiratory distress syndrome (ARDS) However, there are no consistent data about who might benefit most from it Methods: We administered TCZ on a compassionate-use basis to patients with SSP who were hospitalized (excluding intensive care and intubated cases) and who required oxygen support to have a saturation 0 001) in those receiving the drug when the oxygen support was high (FiO2 0 5%) Conclusions: TCZ is well tolerated in patients with SSP, but it has a limited effect on the evolution of cases with high oxygen support needs (C) 2020 The Authors Published by Elsevier Ltd on behalf of International Society for Infectious Diseases

is ?:annotates of